Skip to main content

Avapag 20 mg ( Avatrombopag)

Introduction

Avapag.com aims to provide clear, responsible and educational information about Avapag 20 mg and its stated active ingredient, avatrombopag.

Medical information published on this website may cover the medicine’s pharmacological properties, clinical uses, mechanism of action, dosage considerations, possible adverse reactions, precautions and monitoring requirements.

Reliable medical information is important because prescription medicines require accurate product identification and appropriate clinical supervision.

This page describes the types of authoritative medical and pharmaceutical sources that should be considered when reviewing information about avatrombopag.

Important: The references below support general information about avatrombopag and its established reference product. They do not independently verify Avapag’s manufacturer, formulation, product quality or regulatory authorization.

1. Official Prescribing Information for Doptelet

Document: Doptelet (avatrombopag) tablets — U.S. Prescribing Information.

Organization: U.S. Food and Drug Administration (FDA) and the product’s prescribing-information documentation.

This prescribing information provides important details about the reference avatrombopag tablet product.

Relevant topics include:

  • Approved treatment indications.
  • Dosage and administration.
  • Mechanism of action.
  • Clinical pharmacology.
  • Contraindications and warnings.
  • Adverse reactions.
  • Drug interactions.
  • Use in specific patient populations.
  • Platelet-count monitoring.

The reference prescribing information is useful for understanding the established clinical use of avatrombopag.

However, its instructions should not automatically be treated as the official labeling for Avapag.

2. DailyMed Drug Label Information

Document: DOPTELET — Avatrombopag Maleate Tablets and DOPTELET SPRINKLE Oral Granules.

Organization: U.S. National Library of Medicine, National Institutes of Health.

DailyMed provides official drug-label information submitted to the U.S. Food and Drug Administration.

Relevant information includes:

  • Product identification.
  • Active ingredient information.
  • Dosage forms and strengths.
  • Indications and usage.
  • Dosage and administration.
  • Warnings and precautions.
  • Adverse reactions.
  • Drug interactions.
  • Clinical pharmacology.
  • Patient counseling information.

The DailyMed reference label was updated in August 2025.

3. U.S. Food and Drug Administration

Organization: U.S. Food and Drug Administration (FDA).

The FDA is responsible for evaluating and regulating medicines marketed in the United States.

FDA information is relevant when reviewing:

  • Prescription medicine labeling.
  • Approved therapeutic indications.
  • Drug safety information.
  • Regulatory updates.
  • Product authorization records.
  • Postmarketing safety information.

FDA approval of a particular avatrombopag product does not establish approval of every product containing avatrombopag.

4. Clinical Research on Avatrombopag

Clinical studies provide evidence about the effectiveness and safety of avatrombopag in specific patient populations.

Important research areas include:

Chronic Liver Disease Studies

Clinical trials have evaluated avatrombopag in adults with thrombocytopenia associated with chronic liver disease who were scheduled to undergo medical procedures.

These studies investigated platelet-count responses and the need for platelet transfusion or rescue procedures for bleeding.

Chronic Immune Thrombocytopenia Studies

Clinical research has also evaluated avatrombopag in adults with chronic immune thrombocytopenia who had an insufficient response to previous treatment.

Research has examined:

  • Platelet-count responses.
  • Maintenance of platelet counts.
  • Bleeding-related outcomes.
  • Treatment tolerability.
  • Adverse reactions.
  • Safety during continued treatment.

Clinical research findings should be interpreted in the context of the study population, treatment regimen and limitations.

5. Clinical Pharmacology Information

Clinical pharmacology references help explain how avatrombopag behaves in the body.

Relevant topics include:

  • Absorption.
  • Distribution.
  • Metabolism.
  • Elimination.
  • Pharmacodynamics.
  • Pharmacokinetics.
  • Food-related administration instructions.
  • Drug-metabolizing enzyme interactions.

Avatrombopag activates thrombopoietin receptors and stimulates megakaryocyte development, supporting increased platelet production.

The exact pharmacological and formulation characteristics of Avapag should be confirmed through product-specific documentation.

6. National Medicines Regulatory Authorities

National medicines regulatory authorities are important sources for checking country-specific product authorization.

Depending on the country, these authorities may publish information about:

  • Registered pharmaceutical products.
  • Marketing authorization holders.
  • Approved manufacturers.
  • Product strengths and formulations.
  • Prescription requirements.
  • Safety notices.
  • Product recalls.
  • Regulatory restrictions.

For readers evaluating Avapag, the relevant national regulatory authority should be consulted to establish whether the specific product is authorized in their country.

7. Pharmaceutical Product Documentation

Product-specific documentation is particularly important when reviewing Avapag 20 mg.

The following documents should be considered when available:

  • Original product packaging.
  • Official patient information leaflet.
  • Official prescribing information.
  • Manufacturer documentation.
  • Batch identification records.
  • Product quality documentation.
  • Regulatory registration records.

These documents help distinguish confirmed Avapag-specific details from information that applies only to the active ingredient or another avatrombopag brand.

8. Medical Information About Thrombocytopenia

General medical references about thrombocytopenia help explain the conditions for which avatrombopag may be prescribed.

Important subjects include:

  • Platelet function.
  • Normal platelet production.
  • Causes of thrombocytopenia.
  • Chronic immune thrombocytopenia.
  • Liver disease-associated thrombocytopenia.
  • Bleeding complications.
  • Blood-clotting mechanisms.
  • Platelet-count monitoring.

These subjects provide background for understanding the clinical role of thrombopoietin receptor agonists.

9. How We Evaluate Medical Information

Avapag.com aims to use reliable medical and pharmaceutical information when preparing educational content.

Our editorial approach considers the following principles:

Source reliability: Preference is given to official prescribing information, regulatory documents and recognized medical publications.

Medical accuracy: Statements about clinical uses, dosage and safety should be consistent with reliable medical documentation.

Product transparency: Information about avatrombopag should not automatically be presented as verified information about Avapag.

Safety awareness: Important warnings, adverse reactions and monitoring requirements should be explained clearly.

Regular review: Medical information should be reviewed when significant prescribing or regulatory updates become available.

Clear communication: Technical medical terminology should be explained in language that general readers can understand.

10. Important Distinction Between Avatrombopag and Avapag

One of the most important principles of this website is distinguishing active-ingredient information from product-specific information.

Information categoryWhat it establishes
Avatrombopag clinical informationGeneral information about the active ingredient
Doptelet prescribing informationPrescribing instructions for the reference product
Avapag packagingProduct details printed on the specific product
Manufacturer documentationInformation about the responsible manufacturer
Regulatory recordsAuthorization status in a particular jurisdiction
Product quality documentationEvidence concerning manufacturing and quality requirements

The existence of an approved avatrombopag product does not automatically establish that another brand has identical manufacturing standards, authorization or prescribing instructions.

11. Reference Update Policy

Medical and pharmaceutical information can change over time.

For this reason, the information published on Avapag.com should be reviewed when important updates become available.

Potential reasons for updating website content include:

  • Changes to official prescribing information.
  • New clinical research findings.
  • Updated safety warnings.
  • Changes in regulatory authorization.
  • New product documentation.
  • Corrections to previously published medical information.

When a reference is updated, related website content should also be reviewed to maintain consistency.

12. Limitations of Available References

Although official reference-product information provides useful details about avatrombopag, it does not answer every question about Avapag itself.

The following details require independent product-specific verification:

  • Avapag manufacturer.
  • Manufacturing country.
  • Manufacturing facility.
  • Exact formulation.
  • Product-specific clinical studies.
  • Country-specific registration.
  • Marketing authorization holder.
  • Official Avapag patient information leaflet.

Where reliable documentation is unavailable, these details should be identified as unverified rather than presented as established facts.

Frequently Asked Questions About Medical References

1. What are the main references for avatrombopag information?

Important references include FDA prescribing information, DailyMed drug-label information, clinical research publications and relevant national medicines regulatory records.

2. What is the FDA prescribing information?

It is official drug-label documentation that describes a medicine’s approved indications, dosage instructions, warnings, precautions, adverse reactions and other prescribing information in the United States.

3. What is DailyMed?

DailyMed is a U.S. National Library of Medicine service that provides drug-label information submitted to the FDA.

4. Are Doptelet references relevant to Avapag?

They are relevant for understanding the active ingredient avatrombopag. However, Doptelet-specific manufacturer details, authorization and prescribing instructions should not automatically be attributed to Avapag.

5. Does FDA approval of Doptelet mean Avapag is approved?

No. Authorization of one branded product does not automatically establish authorization of another product containing the same active ingredient.

6. Where can I verify Avapag’s manufacturer?

The manufacturer should be established through the original product packaging, official manufacturer documentation and applicable regulatory records.

7. Why are clinical studies important?

Clinical studies provide evidence about a medicine’s effectiveness, safety, treatment response and possible adverse reactions in specific patient populations.

8. How often should medical references be updated?

References should be reviewed when important regulatory changes, new safety information or relevant clinical research becomes available.

9. Can online medical references replace a doctor?

No. Medical references provide general information but cannot replace individualized medical assessment and professional treatment decisions.

10. Does Avapag.com independently verify every product detail?

Product-specific information should only be described as verified when reliable supporting documentation is available. Unconfirmed details should be clearly identified.

Conclusion

Reliable medical references are essential for understanding avatrombopag, its clinical uses, pharmacological properties, dosage considerations and safety requirements.

Official prescribing information, regulatory documents and clinical research provide valuable information about the active ingredient.

However, reference-brand information must remain separate from Avapag-specific product information.

Avapag.com aims to maintain this distinction and provide educational content that emphasizes accuracy, transparency and responsible medicine use.

Medical Disclaimer

The references and medical information discussed on this page are provided for educational purposes only.

They do not establish the manufacturer, authenticity, quality or regulatory authorization of Avapag 20 mg.

Prescribing instructions for another avatrombopag brand should not automatically be applied to Avapag.

Always consult the official documentation for the specific medicine and seek advice from a qualified healthcare professional before starting, changing or stopping treatment.